Oryzon Genomics S.A. Logo

Oryzon Genomics S.A.

ISIN

ES0167733015

Ticker

ORY

Sector

Health Care

Sub-Industry

Biotechnology

Country

Spain

Year Founded

2000

About Oryzon Genomics S.A.

Company Description

Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.

Headcount

43

Served Area

Europe + North America

Headquarters

Carrera de San Jeronimo 15
28014, Madrid
Spain

Filings & Publications

  • Consolidated Report 2019 - Q4 Spanish 🇪🇸
  • Consolidated Report 2018 - Q4 Spanish 🇪🇸
  • Consolidated Report 2017 - Q4 Spanish 🇪🇸
  • Consolidated Report 2016 - Q4 Spanish 🇪🇸
  • Consolidated Report 2015 - Q4 Spanish 🇪🇸
  • Consolidated Report 2014 - Q4 Spanish 🇪🇸
  • Consolidated Report 2013 - Q4 Spanish 🇪🇸
  • Consolidated Report 2012 - Q4 Spanish 🇪🇸

Capital Markets Information

ISIN

ES0167733015

LEI

95980063R15RDF29DK13

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Bolsa de Madrid

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.